Chronic Obstructive Pulmonary Disease (COPD). Other chronic obstructive pulmonary disease
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will take oral pearl Vitamin D3 (50,000 IU) weekly for 8 weeks. Then, They receive this dose of Vitamin D3 every two weeks for 4 months (Tota
Treatment - Drugs
Placebo
Intervention group: Patients in this group will take oral pearl Vitamin D3 (50,000 IU) weekly for 8 weeks. Then, They receive this dose of Vitamin D3 every two weeks for 4 months (Totally 16 doses).
Control group: Patients in this group will take a placebo exactly the same as the intervention group.
Sponsors
North Khorasan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with vitamin level more than 20 nano gram per milli liter; age more than 40;patients with diagnosis of severe and very severe COPD; patients who complete the consent form Exclusion criteria: Patient who receive vitamin D supplementation more than 400 unit per day; taking daily dose of systemic corticosteroid(oral or ingection) as maintenance; personal history of one of the following diseases: Osteoporosis, Asthma, renal failure, liver failure, Nephrolithiasis, Hypercalcemia, active TB, Malignancy, Sarcoidosis, Malabsorption; pregnancy and lactation or individuals who want to be pregnant during the study; using of antileptic drugs(barbitorat and phenytoin,) and alcohol; patient with psychological problem; unreliable patients in study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of quality of life. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: m-MRC Questionnaire.;The time of first acute exacerbation. Timepoint: During the study. Method of measurement: Recording in the patients’ information form.;Evaluation of quality of life. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: SGQR-C Questionnaire.;Evaluation of quality of life. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: CAT Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of hospitalization. Timepoint: During the study. Method of measurement: Recording in the patients’ information form.;Length of stay. Timepoint: During the study. Method of measurement: Recording in the patients’ information form.;Serum level of 25-hydroxyvitamin D. Timepoint: At time of inclusion, 1, 3, and 6 months after treatment. Method of measurement: Measurement of serum level. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Bagher Oghazian
Faculty of Internal Medicine, North Khorasan University of Medical Sciences
Outcome results
None listed